1. Home
  2. LIXT vs NVVE Comparison

LIXT vs NVVE Comparison

Compare LIXT & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
    SELLHOLDBUYas of 21 hours ago
  • NVVE
    SELLHOLDBUYas of 21 hours ago
  • Stock Information
  • Founded
  • LIXT 2005
  • NVVE 1996
  • Country
  • LIXT United States
  • NVVE United States
  • Employees
  • LIXT N/A
  • NVVE N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • NVVE Oil Refining/Marketing
  • Sector
  • LIXT Health Care
  • NVVE Energy
  • Exchange
  • LIXT Nasdaq
  • NVVE Nasdaq
  • Market Cap
  • LIXT 4.1M
  • NVVE 3.7M
  • IPO Year
  • LIXT N/A
  • NVVE N/A
  • Fundamental
  • Price
  • LIXT $1.17
  • NVVE $1.00
  • Analyst Decision
  • LIXT
  • NVVE
  • Analyst Count
  • LIXT 0
  • NVVE 0
  • Target Price
  • LIXT N/A
  • NVVE N/A
  • AVG Volume (30 Days)
  • LIXT 31.2K
  • NVVE 176.6K
  • Earning Date
  • LIXT 03-24-2025
  • NVVE 03-31-2025
  • Dividend Yield
  • LIXT N/A
  • NVVE N/A
  • EPS Growth
  • LIXT N/A
  • NVVE N/A
  • EPS
  • LIXT N/A
  • NVVE N/A
  • Revenue
  • LIXT N/A
  • NVVE $5,286,229.00
  • Revenue This Year
  • LIXT N/A
  • NVVE $200.61
  • Revenue Next Year
  • LIXT N/A
  • NVVE $109.43
  • P/E Ratio
  • LIXT N/A
  • NVVE N/A
  • Revenue Growth
  • LIXT N/A
  • NVVE N/A
  • 52 Week Low
  • LIXT $1.02
  • NVVE $0.96
  • 52 Week High
  • LIXT $3.74
  • NVVE $17.30
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 38.93
  • NVVE 26.50
  • Support Level
  • LIXT $1.15
  • NVVE $1.53
  • Resistance Level
  • LIXT $1.29
  • NVVE $1.16
  • Average True Range (ATR)
  • LIXT 0.09
  • NVVE 0.15
  • MACD
  • LIXT 0.02
  • NVVE -0.02
  • Stochastic Oscillator
  • LIXT 10.71
  • NVVE 4.85

Stock Price Comparison Chart: LIXT vs NVVE

LIXT
NVVE
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April05101520253035LIXT VS NVVE

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NVVE Nuvve Holding Corp.

Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use